The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Solov'eva É.Iu.

Kafedra nevrologii FUV GOU VPO RGMU, Moskva

Dzhutova E.D.

Pirogov Russian National Research Medical University, Moscow, Russia

Knyazeva V.S.

Pirogov Russian National Research Medical University, Moscow, Russia

Pathogenetic approaches to treatment of cognitive disorders in patients with diabetes mellitus

Authors:

Solov'eva É.Iu., Dzhutova E.D., Knyazeva V.S.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(7): 85‑93

DOI: 10.17116/jnevro20161167185-93

Views: 1882

Downloaded: 53

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Solov'eva ÉIu, Dzhutova ED, Knyazeva VS. Pathogenetic approaches to treatment of cognitive disorders in patients with diabetes mellitus. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(7):85‑93. (In Russ.)
https://doi.org/10.17116/jnevro20161167185-93

 
МСФ на ЯМ
Close metadata
Recommended articles:
Effi­cacy of Mexi­dol in combination with cere­bral reva­scularization in the treatment of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):67-74
Asso­ciations between components of meta­bolic syndrome and cognitive impairment in patients with schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):82-87
Prevalence of cognitive impairment in older adults in the Russian Fede­ration. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):5-11
Cognitive impairment in cere­brovascular diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):12-16
Endo­thelial dysfunction as a pathogenetic factor of sensorineural hearing loss. Russian Bulletin of Otorhinolaryngology. 2024;(1):21-27
Causes of hospital mortality in adults based on medi­cal certificates of death. Russian Journal of Preventive Medi­cine. 2024;(3):7-13
Prevalence of cardiovascular diseases risk factors in Maga­dan schoolchildren. Russian Journal of Preventive Medi­cine. 2024;(3):39-44
Oxidative stress prevention as an effe­ctive preventive stra­tegy in type 2 diabetes mellitus. Russian Journal of Preventive Medi­cine. 2024;(3):117-123
Opti­mizing the treatment of diabetic ketoacidosis. Russian Journal of Anesthesiology and Reanimatology. 2024;(2):67-77
Modern issues of lung tube­rculosis and diabetes mellitus on the toba­cco consumption background in the world and the Russian Fede­ration. Russian Journal of Preventive Medi­cine. 2024;(4):97-102

The article presents the currents concepts on the mechanisms of brain lesions and development of cognitive impairment in diabetes mellitus (DM) including DM type 2. Metabolic and vascular mechanisms, oxidative stress, hyperglycemia, glutamate excitotoxicity, insulin insufficiency and brain insulin resistance, general vascular and microcirculatory disturbances, death of cortical neurons, decrease in the newly synthesized acetylcholine, activation of lipid peroxidation are considered. A review of the main domestic and international drugs used in clinical practice for treatment of cognitive impairment in patients with DM is presented.

Keywords:

diabetes mellitus
cognitive disorders
dementia
oxidative stress
emoxypine
succinic acid
choline alfoscerate
hyperglycemia

Authors:

Solov'eva É.Iu.

Kafedra nevrologii FUV GOU VPO RGMU, Moskva

Dzhutova E.D.

Pirogov Russian National Research Medical University, Moscow, Russia

Knyazeva V.S.

Pirogov Russian National Research Medical University, Moscow, Russia

List of references:

  1. Biessels GJ. Cerebral complications of diabetes: clinical findings and pathogenetic mechanisms. The Netherlands Journal of Medicine. 1999;54:35-45. doi: 10.1016/S0300-2977(98)00134-X
  2. Ryan CM, Geckle MO. Circumscribed cognitive dysfunction in middle-aged adults with type 2 diabetes. Diabetes Care. 2000;23:1486-1493. doi: 10.2337/diacare.23.10.1486.
  3. Strokov IA, Zaharov VV, Strokov KI. Diabeticheskaja jencefalopatija. Nevrologija, nejropsihiatrija, psihosomatika. 2012;4(2):30-40. doi: 10.14412/2074-2711-2012-2506
  4. Shprah VV, Falieva EM, Akulova EM, Sajutina SB, Mihalevich IM. Discirkuljatornaja jencefalopatija u bol'nyh saharnym diabetom. Nevrologicheskij zhurnal. 1998;6:32-34. (In Russ.).
  5. Mattis S. Mental status examination for organic mental syndrome in the elderly patients. In: Bellack L., Karasu TB., eds. Geriatric Psychiatry. New York: Grunea Sratton; 1976;383.
  6. Cox DJ, Kovatchev BP, Gonder-Frederick LA et al. Relationships Between Hyperglycemia and Cognitive Performance Among Adults With Type 1 and Type 2 Diabetes. Diabetes Care. 2005;28(1):71-77. doi: 10.2337/diacare.28.1.71.
  7. Strachan MWJ, Reynolds RM, Frier BM, Mitchell RJ, Price JF. The relationship between type 2 diabetes and dementia. British Medical Bulletin. 2008;88(1):131-146. doi: 10.1093/bmb/ldn042
  8. Mijnhout GS, Scheltens P, Diamant M, Wessels AM, Simsek S, Heine RJ. Diabetic encephalopathy: a concept in need of a definition. Diabetologia. 2006;49(6):1447-1448. doi: 10.1007/s00125-006-0221-8
  9. Bruce DG, Casey GP, Drange V, Clarnette RC, Almeida OP, Foster JK, Davis TME. Cognitive impairment, physical disability and depressive symptoms in older diabetic patients: the Fremantle Cognition in Diabetes Study. Diabetes Research and Clinical Practice. 2003;61(1):59-67. doi: 10.1016/s0168-8227(03)00084-6
  10. Gregg EW, Brown AA. Cognitive and physical disabilities and aging-related complications of diabetes. Cognitive and Physical Disabilities and Aging-Related Complications of Diabetes. Clinical Diabetes. 2003;21(3):113-118. doi: 10.2337/diaclin.21.3.113
  11. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. The Lancet Neurology. 2006;5(1):64-74. doi: 10.1016/s1474-4422(05)70284-2
  12. Cukerman T, Gerstein HC, Willamson JD. Cognitive decline and dementia in diabetes - systematic overview of prospective observation studies. Diabetologia. 2005;48(12):2460-2469. doi: 10.1007/s00125-005-0023-4
  13. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703-713. doi: 10.1136/bmj.317.7160.703
  14. Wredling R, Levander S, Adamson U, Lins PE. Permanent neuropsychological impairment after recurrent episodes of severe hypoglycaemia in man. Diabetologia. 1990;33(3):152-157. doi: 10.1007/bf00404042
  15. Firsov AA, Mashhenko EA. Kognitivnye narushenija pri saharnom diabete u lic pozhilogo vozrasta. Arhiv vnutrennej mediciny. 2014;4(18):26-31. (In Russ.).
  16. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of dementia in a multiethnic cohort . American Journal of Epidemiology. 2001;154(7):635-641. doi: 10.1093/aje/154.7.635
  17. Xu WL, Qiu CX, Wahlin A, Winblad B, Fratiglioni L. Diabetes mellitus and risk of dementia in the Kungsholmen project: A 6-year follow-up study. Neurology. 2004;63(7):1181-1186. doi: 10.1212/01.wnl.0000140291.86406.d1
  18. de la Monte SM, Wands JR. Alzheimer’s disease is type 3 diabetes-evidence reviewed. Journal of Diabetes Science and Technology. 2008;2(6):1101-1113. doi: 10.1177/193229680800200619
  19. Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M, Nawata H. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes. 2000;49(11):1939-1945. doi: 10.2337/diabetes.49.11.1939.
  20. Esin RG, Hajrulin IH, Esin OR. Sovremennye predstavlenija o mehanizmah kognitivnyh rasstrojstv pri saharnom diabete. Medicinskij al'manah. 2013;1(25):135-138. (In Russ.).
  21. Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes. 2002;51(4):1256-1262. doi: 10.2337/diabetes.51.4.1256
  22. Messier C. Diabetes, Alzheimer's disease and apolipoprotein genotype. Experimental Gerontology. 2003;38(9):941-946. doi: 10.1016/S0531-5565(03)00153-0
  23. Etgen T, Sauder D, Bichel H, Sander K, Forstl H. Cognitive decline: the relevance of diabetes, hyperlipidaemia and hypertension. The British Journal of Diabetes & Vascular Disease. 2010;10(3):115-122. doi: 10.1177/1474651410368408
  24. Hassing LB, Hofer SM, Nilsson SE, Berg S, Pedersen NL, McClearn G, Johansson B. Comorbid type 2 diabetes mellitus and hypertension exacerbates cognitive decline: evidence from a longitudinal study. Age and Ageing. 2004;33(4):355-361. doi: 10.1093/ageing/afh100
  25. Posner HB, Tang MX, Luchsinger J, Lantigua R, Stern Y, Mayeux R. The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function. Neurology. 2002;58(8):1175-1181. doi: 10.1212/wnl.58.8.1175
  26. MacKnight C, Rockwood K, Awalt E, McDowell I. Diabetes mellitus and the risk of Alzheimer’s disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dementia and Geriatric Cognitive Disorders. 2002;14(2):77-83. doi: 10.1159/000064928
  27. Chugunov PA, Semenova IV, Orlov JuJu, Shestakova MV. Saharnyj diabet i kognitivnye narushenija. Saharnyj diabet. 2008;1:61-68. doi: 10.14341/2072-0351-5948 (In Russ.).
  28. McGuire LC, Ford ES, Ajani UA. The impact of cognitive functioning on mortality and the development of functional disability in older adults with diabetes: the second longitudinal study on aging. BMC Geriatrics. 2006;6(1):8. doi: 10.1186/1471-2318-6-8
  29. Kodl CT, Seaquist ER. Cognitive dysfunction and diabetes mellitus. Endocrine Reviews. 2008;29(4):494-511. doi: 10.1210/er.2007-0034
  30. Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Current Pharmaceutical Design. 2005;11(18):2279-2299. doi: 10.2174/1381612054367300
  31. Nielson KA, Nolan JH, Berchtold NC, Sandman C, Mulnard RA, Cotman CW. Apolipoprotein-E genotyping of diabetic dementia patients: is diabetes rare in Alzheimer’s disease? Journal of the American Geriatrics Society. 1996;44(8):897-904. doi: 10.1111/j.1532-5415.1996.tb01857.x
  32. Sima AA, Kamiya H, Li ZG. Insulin, C-peptide, hyperglycemia, and central nervous system complications in diabetes. European Journal of Pharmacology. 2004;490(1-3):187-197. doi: 10.1016/j.ejphar.2004.02.056
  33. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. The Journal of the American medical Associaton. 2002;287(19):2570. doi: 10.1001/jama.287.19.2570
  34. Efimov AS. Diabeticheskie angiopatii. M.: Medicina; 1989: 288. (In Russ.).
  35. Brookes PS, Levonen A-L, Shiva S, Sarti P, Darley-Usmar VM. Mitochondria: regulators of signal transduction by reactive oxygen and nitrogen Free Radical Biology and Medicine. 2002;33(6):755-764. doi: 10.1016/s0891-5849(02)00901-2
  36. Satarkov AA, Fiskum G, Chinopoulos C, Lorenzo BJ, Browne SE, Patel MS, Beal MF. Mitochondrial α-ketoglutarate dehydrogenase complex generates reactive oxygen species. Journal of Neuroscience. 2004;24:7779-7788. doi: 10.1523/jneurosci.1899-04.2004
  37. Boullier A, Bird DA, Chang MK, Dennis EA, Friedman P, Gillotre-Taylor K, Hörkkö S, Palinski W, Quehenberger O, Shaw P, Steinberg D, Terpstra V, Witztum JL. Scavenger receptors, oxidized LDL, and atherosclerosis. Annals of the New York Academy of Sciences. 2001;947:214-222. doi: 10.1111/j.1749-6632.2001.tb03943.x
  38. Kiray M, Bagriyanik HA, Pekcetin C, Ergur BU, Uysal N, Ozyurt D, Buldan Z. Deprenyl and the relationship between its effects on spatial memory, oxidant stress and hippocampal neurons in aged male rats. Physiological Research. 2006;55(2):205-212.
  39. Voronina TA. Meksidol: spektr farmakologicheskih jeffektov. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2012;12:86-90. (In Russ.)
  40. Voronina TA. Antioksidant meksidol. Osnovnye nejropsihotropnye jeffekty i mehanizm dejstvija. Psihofarmakologija i biologicheskaja narkologija. 2001;1(1):2-12. (In Russ.).
  41. Val'dman AV, Voronina TA, Smirnov LD. Vlijanie proizvodnyh 3-oksipiridinov na central'nuju nervnuju sistemu. Bjulleten' jeksperimental'noj biologii i mediciny. 1985;1:60-62. (In Russ.).
  42. Djumaev KM, Voronina TA, Smirnov LD. Antioksidanty v profilaktike i terapii patologij CNS. M.: Izdatel'stvo Instituta biomedicinskoj himii; 1995. (In Russ.).
  43. Voronina TA, Smirnov LD, Gorjajnova II. Mehanizm dejstvija i obosnovanie primenenija preparata meksidol v nevrologii: metodicheskie rekomendacii. M.: Inctitut biohimicheskoj fiziki, NII farmakologii RAMN. 2002. (In Russ.).
  44. Fedin AI, Rumjanceva SA, Mironova OP, Evseev VN. Primenenie antioksidanta «Meksidol» u bol'nyh s ostrym narusheniem mozgovogo krovoobrashhenija: metodicheskie rekomendacii. M.: RGMU; 2002. (In Russ.).
  45. Burlakova EB, Kajrane ChB, Molochkina EM, Hohlov AP. Modifikacija lipidov naruzhnoj membrany mitohondrij pecheni myshej i kineticheskih parametrov membranosvjazannoj monoaminoksidazy in vivo i in vitro. Voprosy medicinskoj himii. 1984;1:66-71. (In Russ.).
  46. Volchegorskij IA, Miroshnichenko IJu, Rassohina LM, Malkin MP, Fajzulin RM, Prjahina KE, Kalugina AV. Antidepressivnoe dejstvie proizvodnyh 3-oksipiridina i jantarnoj kisloty v jeksperimente. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2015;115(2):48-52.  doi: 10.17116/jnevro20151152148-5 (In Russ.).
  47. Volchegorskij IA, Mester NV. Vlijanie proizvodnyh 3-oksipiridina na projavlenija depressii i kognitivnye funkcii u bol'nyh saharnym diabetom. Biomedicina. 2006;3:98-100. (In Russ.).
  48. Chashhina EN. Sravnitel'nyj analiz vlijanija proizvodnyh 3-oksipiridina i jantarnoj kisloty na projavlenija distal'noj simmetrichnoj polinejropatii u bol'nyh saharnym diabetom s sindromom diabeticheskoj stopy: Dis. kand. med. nauk. Cheljabinsk; 2005. Ssylka aktivna na 22.03.16. Dostupno po: http://dlib.rsl.ru/loader/view/01002941986?get=pdf (In Russ.).
  49. Tanashjan MM, Lagoda OV, Antonova KV. Hronicheskie cerebrovaskuljarnye zabolevanija na fone metabolicheskoju sindroma: novye podhody k lecheniju. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2012;112(11):21-26. (In Russ.).
  50. Volchegorskij NA, Rassohina LM, Miroshnichenko IJu. Cerebroprotektivnye jeffekty jemoksipina, reamberina i meksidola pri alloksanovom diabete. Bjulleten' jeksperimental'noj biologii i mediciny. 2013;155(1):56-64. doi: 10.1007/s10517-013-2079-3 (In Russ.).
  51. Zamora M, Pardo R, Villena JA. Pharmacological induction of mitochondrial biogenesis as a therapeutic strategy for the treatment of type 2 diabetes. Biochemical Pharmacology. 2015;98(1):16-28. doi: 10.1016/j.bcp.2015.06.032
  52. Klebanov GI, Ljubickij OB, Vasil'eva OV, Klimov JuV, Penzulaeva OB, Tepljashin AS, Tolstyh MP, Promorenko VK, Vladimirov JuA. Antioksidantnye svojstva proizvodnyh 3-oksipiridina: meksidola, jemoksipina i proksipina. Voprosy medicinskoj himii. 2001;47:288-300. (In Russ.).
  53. Duma SN, Ragino JuI. Rol' antioksidantov v korrekcii psihovegetativnyh, astenicheskih i kognitivnyh narushenij. Trudnyj pacient. 2011;9(4):8-15. (In Russ.).
  54. Tayebati SK, Amenta F. Choline-containing phospholipids: relevance to brain functional pathways. Clinical Chemistry and Laboratory Medicine. 2013;51(3). doi: 10.1515/cclm-2012-0559
  55. Scapicchio PL. Revisiting choline alphoscerate profile: a new, perspective, role in dementia? International Journal of Neuroscience. 2013;123(7):444-449. doi: 10.3109/00207454.2013.765870
  56. Ushkalova EA. Ushkalova AV. Farmakoterapija kognitivnyh narushenij razlichnogo geneza: sovremennoe sostojanie i perspektivnye napravlenija. Russkij medicinskij zhurnal. 2014;22:1613-1617. (In Russ.).
  57. Parnetti L, Mignini F, Tomassoni D, Traini E, Amenta F. Cholinergic precursors in the treatment of cognitive impairment of vascular origin: Ineffective approaches or need for re-evaluation? Journal of the Neurological Sciences. 2007;257(1-2):264-269. doi: 10.1016/j.jns.2007.01.043
  58. Sangiorgi GB, Barbagallo M, Giordano M, Meli M, Panzarasa R. α-Glycerophosphocholine in the Mental Recovery of Cerebral Ischemic Attacks. Annals of the New York Academy of Sciences. 1994;717(1):253-269. doi: 10.1111/j.1749-6632.1994.tb12095.x
  59. Kamchatnov PR, Abusueva BA, Evzel'man MA, Esin RG, Kol'jak EV, Novikova LB, Prikazchikov SV, Rjabov AG, Umarova HJa, Bojko A.N. Jeffektivnost' ceretona pri ostrom ishemicheskom insul'te (rezul'taty issledovanija SOLNCE). Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2012;3(2):10-14. (In Russ.).
  60. Levin OS, Batukaeva LA, Anikina MA, Junishhenko NA. Jeffektivnost' i bezopasnost' holina al'foscerata (ceretona) u pacientov s bolezn'ju Parkinsona s kognitivnymi narushenijami. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2009;109(11):42-46. (In Russ.).
  61. Traini E, Bramanti V, Amenta F. Choline alphoscerate (alpha-glyceryl-phosphoryl-choline) an old choline-containing phospholipid with a still interesting profile as cognition enhancing agent. Current Alzheimer Research. 2013;10(10):1070-1079. doi: 10.2174/15672050113106660173
  62. Amenta F, Carotenuto A, Fasanaro AM, Rea R, Traini E. The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer’s disease with cerebrovascular injury: interim results. Journal of the Neurological Sciences. 2012;322(1-2):96-101. doi: 10.1016/j.jns.2012.07.003
  63. Shmyrev VI, Kryzhanovskij SM. Kombinirovannaja terapija ishemicheskogo insul'ta holina al'fosceratom i jetilmetilgidroksipiridina sukcinatom. Farmateka. 2013;9:79-83. (In Russ.).
  64. Seregin VI. Primenenie gliatilina i meksidola v intensivnoj terapii tjazhelogo ostrogo ishemicheskogo insul'ta. Farmateka. 2006;5. (In Russ.).
  65. Gennis R. Biomembrany: Molekuljarnaja struktura i funkcii. M.: Mir; 1997.
  66. Bazan NG, eds. Neuronal cell signal transduction and second messengers in cerebral ischemia. Stuttgart: Wissenschaftliche Verlagsgesellschaft; 1990.
  67. Siesjö BK. Hypoglycemia, brain metabolism, and brain damage. Diabetes / Metabolism Reviews. 1988;4(2):113-144. doi: 10.1002/dmr.5610040203
  68. Agut J, Font E, Sacristn A, Ortiz JA. Radioactivity incorporation into different cerebral phospholipids after oral administration of 14C methyl CDP-choline. Arzneimittelforschung. 1983;33:1048-1050.
  69. D’Orlando KJ, Sandage BW Jr. Citicoline (CDP-choline): mechanisms of action and effects in ischemic brain injury. Neurological Research. 1995;17:281-284. doi: 10.1046/j.0022-3042.2001.00697.x
  70. Rao AM, Hatcher JF, Dempsey RJ. Does CDP-choline modulate phospholipase activities after transient forebrain ischemia? Brain Research. 2001;893(1-2):268-272. doi:10.1016/s0006-8993(00)03280-7
  71. Adibhatla RM, Hatcher JF. Citicoline decreases phospholipase A2 stimulation and hydroxyl radical generation in transient cerebral ischemia. Journal of Neuroscience Research. 2003;73(3):308-315. doi: 10.1002/jnr.10672.
  72. Zweifler RM. Membrane Stabilizer: Citicoline. Current Medical Research and Opinion. 2002;18(suppl 2):14-17. doi: 10.1185/030079902125000679
  73. Barancevich ER, Posohina OV. Podhody k terapii nevrologicheskih projavlenij saharnogo diabeta Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2010;4:63-67. (In Russ.).

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.